

Christina L Fanola

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/131872/publications.pdf>

Version: 2024-02-01

8
papers

445
citations

1478505

6
h-index

1720034

7
g-index

9
all docs

9
docs citations

9
times ranked

1040
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patientsâ€“Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. American Heart Journal, 2018, 202, 39-48.	2.7	15
2	TIMIâ€“AF score and cardiovascular events in vitamin K antagonistsâ€“naÃ“ve outpatients with atrial fibrillation. Clinical Cardiology, 2018, 41, 1252-1258.	1.8	4
3	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. New England Journal of Medicine, 2018, 379, 1107-1117.	27.0	205
4	A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. European Heart Journal, 2017, 38, ehw565.	2.2	37
5	EFFICACY AND SAFETY OF EDOXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AND ACTIVE MALIGNANCY: AN ANALYSIS OF ENGAGE AF â€“ TIMI 48 RANDOMIZED CLINICAL TRIAL. Journal of the American College of Cardiology, 2017, 69, 325.	2.8	159
6	BLOOD PRESSURE, SUBCLINICAL MYOCARDIAL INJURY AND CARDIOVASCULAR OUTCOMES AMONG PATIENTS WITH DIABETES AND HIGH CARDIOVASCULAR RISK: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL. Journal of the American College of Cardiology, 2017, 69, 1653.	2.8	0
7	Incidence of severe renal dysfunction among individuals taking warfarin and implications for nonâ€“vitamin K oral anticoagulants. American Heart Journal, 2017, 184, 150-155.	2.7	18
8	Current and emerging strategies in the management of venous thromboembolism: benefit–risk assessment of dabigatran. Vascular Health and Risk Management, 2015, 11, 271.	2.3	7